Shyam Patel’s Post

CIRM has approved awarding $31 million for clinical trial research. The awards will support clinical research at Luxa Biotechnology LLC to find a cell treatment for dry age-related macular degeneration (AMD), impacting almost 19.8 million people in the United States. The awards will also help fund a multi-site trial led by the University of California, San Francisco, exploring the potential of a gene therapy targeting cancers that form in the brain and spinal cord. Additionally, a $15 million award to Allogene Therapeutics will support the development of a CAR-T cell product designed to treat metastatic clear cell renal cell carcinoma, the most common kidney cancer. https://lnkd.in/gwNm-Cx6 #RegenerativeMedicine #ClinicalTrials #Research #GeneTherapy #StemCells

🚀 Exciting advancements in oncology research! 🧬 Novel oncology mechanisms, including cell and gene therapies, ADCs, and multispecific antibodies, now account for 25% of all clinical trials, up from previous years. This shift highlights the growing importance of innovative therapies in the fight against cancer. 🌟 #OncologyResearch #CancerTherapies #InnovationInOncology #ClinicalTrials #MedicalResearch #OncologyAdvancements #CellTherapy #GeneTherapy #ADCs #Antibodies #HealthcareInnovation #BiotechResearch #PrecisionMedicine #CancerTreatment #OncologyDevelopment #HealthcareTrends #Biopharma #HealthTech #MedicalInnovation #ClinicalResearch #GlobalHealthcare #HealthcareIndustry #MedTech #BiomedicalResearch #CancerResearch #ClinicalTrialTrends #HealthcareLeadership #FutureOfHealthcare

To ensure patient access to CGTs, we must address the scalability challenge now... The FDA has recently approved two CGT therapies: 🧬 Bristol Myers Squibb's Breyanzi® has been awarded accelerated approval to expand it's treatment indications to include relapsed or refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma 🧬 Orchard Therapeutics™ Lenmeldy™ is now the first gene therapy for Metachromatic Leukodystrophy With the ongoing clinical success across the sector it's no suprise we're seeing a rush of accelerated approvals, the question now is how do we support the commercial viability of these therapies? As an industry, now is the time to take stock to ensure we are equipped to manufacture these incredible therapies at scale and bring them to the patients that need them most. Read more: 1️⃣ https://lnkd.in/d-xc4Ce2 2️⃣ https://lnkd.in/eJ85TdjK #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess

📢 Press Release: Elicera enters agreement with prominent US Cancer Center to evaluate the use of iTANK in T-cell receptor therapies Elicera Therapeutics AB, a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, announces that the company has entered a Material Transfer Agreement (MTA) with a prominent US Center. Via the agreement, the enhancing effect of the iTANK-technology will be evaluated in a novel T-cell receptor therapy targeting #skincancer and #lungcancer Jamal El-Mosleh, Elicera's CEO comments, ...''Importantly, the collaboration will give us key insights into the potential of broader applicability of the iTANK-platform, as it will be investigated for arming a T-cell receptor therapy, an important complement to previous studies arming studies performed exclusively in CAR T-cells''. 👉 Read the full press release on our website: https://lnkd.in/etPxKYnV #celltherapy #genetherapy

This was a big week for early-stage cell and gene therapies. 🔬World’s first TIL therapy for liver cancer cleared for US clinical trials 🧬Base editing therapy has IND cleared by the FDA 🧫 The FDA clears IND for NK cell therapy to treat Alzheimer’s disease Read the full news roundup. ⬇️ BioSyngen's BST02, the world's first TIL therapy for liver cancer, is granted an IND approval by the FDA. #livercancer https://lnkd.in/gFudfgK5 Verve Therapeutics announces clearance of IND application by the U.S. FDA for base editing therapy in patients with heterozygous familial hypercholesterolemia. #baseediting #genetherapy https://lnkd.in/gk4UyRxp NKGen Biotech, Inc. announces FDA clearance of IND application for SNK01 NK cell therapy to treat Alzheimer’s disease. #celltherapy #Alzheimers https://lnkd.in/g32AuWUn

Watch this on-demand webinar on recent progress in cancer research, including novel treatments, experimental therapies, and drug development. In this session, Aptamer Group CSO, David Bunka discusses how Optimer technology is enabling new strategies in cancer treatment, including the targeted delivery of diverse payloads to cancer cells for precision chemotherapy, or gene therapy approaches. https://lnkd.in/ebhQpQXD

Asgard Therapeutics announces the selection of Exothera for process development up to clinical Phases I/II manufacturing of lead program AT-108. AT-108 is a first-in-class, off-the-shelf gene therapy that leads to personalized and potent anti-cancer immune responses. This partnership marks a significant milestone for Asgard Therapeutics as we progress towards clinical development. We are thrilled to work with Exothera - a leading provider of nucleic acid and viral vector development and manufacturing services. Click the link in the comments below to read the full press release and discover more about our groundbreaking approach to in vivo direct cell reprogramming for cancer immunotherapy. #immunotherapy #biotech #manufacturing

📖 Read the article: https://lnkd.in/gByvf64T 🌟 The gene-modified cell therapy field continues to grow apace, particularly in the oncology arena, which dominates both preclinical and clinical applications. We interviewed industry thought leaders in collaboration with the team at Cell & Gene Therapy Insights to provide you with the latest trends for #gene-modified cell therapy. #Oncology #GeneTherapy #Biotechnology

Explore DNA methylation and its intricate role in cancer, where dysregulation of 5-methylcytosine (5mC) impacts gene regulation. Aberrant methylation patterns in CpG dinucleotides contribute to tumor suppressor gene silencing and oncogene activation. Seraseq® Methylated and Unmethylated ctDNA Mutation Mixes provide unparalleled insight into CpG methylation status, revolutionizing cancer research and personalized treatment approaches. Read our blog and discover the potential of DNA methylation in cancer diagnostics and therapy: https://hubs.ly/Q02vLxb20 #Methylation #GeneRegulation #DNAModification #CancerResearch #Epigenetics